N-(4-(3-bromophenylamino)quinolin-6-yl)-4-(dimethylamino)butanamide | 1219717-65-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(4-(3-bromophenylamino)quinolin-6-yl)-4-(dimethylamino)butanamide
• 英文别名: N-(4-(3-Bromophenylamino)quinolin-6-yl)-4-(dimethylamino)-butanamide；N-[4-(3-bromoanilino)quinolin-6-yl]-4-(dimethylamino)butanamide
• CAS: 1219717-65-3
• 化学式: C₂₁H₂₃BrN₄O
• 分子量: 427.344
• InChiKey: PHFAEZLTGYDQNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  57.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-4-(3-bromophenyl)quinoline-4,6-diamine 、 4-(dimethylamino)butanoyl chloride hydrochloride 以 N-甲基吡咯烷酮 为溶剂， 以41%的产率得到N-(4-(3-bromophenylamino)quinolin-6-yl)-4-(dimethylamino)butanamide
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor

  摘要：

  The mutant receptor tyrosine kinase EGFR is a validated and therapeutically amenable target for genotypically selected lung cancer patients. Here we present the synthesis and biological evaluation of a series of 6- and 7-substituted 4-anilinoquinolines as potent type I inhibitors of clinically relevant mutant variants of EGFR. Quinolines 3a and 3e were found to be highly active kinase inhibitors in biochemical assays and were further investigated for their biological effect on EGFR-dependent Ba/F3 cells and non-small cell lung cancer (NSCLC) cell lines.

  DOI：

  10.1021/jm901877j

文献信息

• Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor
  作者：Vijaykumar G. Pawar、Martin L. Sos、Haridas B. Rode、Matthias Rabiller、Stefanie Heynck、Willem A. L. van Otterlo、Roman K. Thomas、Daniel Rauh

  DOI：10.1021/jm901877j

  日期：2010.4.8

  The mutant receptor tyrosine kinase EGFR is a validated and therapeutically amenable target for genotypically selected lung cancer patients. Here we present the synthesis and biological evaluation of a series of 6- and 7-substituted 4-anilinoquinolines as potent type I inhibitors of clinically relevant mutant variants of EGFR. Quinolines 3a and 3e were found to be highly active kinase inhibitors in biochemical assays and were further investigated for their biological effect on EGFR-dependent Ba/F3 cells and non-small cell lung cancer (NSCLC) cell lines.